

**Yosr BOUSSOUKAYA**  
Faculty of medicine of Monastir

**& Nader BEN NEJMA**  
Faculty of medicine of Tunis

•First discovered in the 70s in patients with **systemic lupus erythematosus (SLE)**.

•**Target antigen:** ribosomal phosphoprotein P0 (38 kDa), P1 (19 kDa) and P2 (17 kDa) of the subunit 60S.

•Low prevalence (10% of SLE patients)  
•**BUT highly specific (>90%)**  
•Could be present even in individuals with negative anti-dsDNA or anti-Sm antibodies.

•**Not included** in the classification criteria for SLE.  
•Most useful for the diagnosis of SLE when other specific autoantibodies are negative (early diagnosis/ avoid missed diagnoses).  
•Suggested association with **neuropsychiatric** (up to 90% of patients, but data is controversial), **renal** (up to 35% of patients) and **cutaneous involvement (mostly acute lesions)** in SLE.



•Probably associated with liver damage (lupus hepatitis and autoimmune hepatitis in non SLE patients)

**Screening technique:**  
Indirect immunofluorescence on HEp-2 cells

•**IIF pattern on HEp-2 cells:**  
dense-grained cytoplasmic fluorescence= very fine, tightly-packed punctuations distributed throughout the cytoplasm, with perinuclear enhancement

**Anti-ribosomal proteins antibodies**

•Often associated with other anti-nuclear antibody (ANA) fluorescence patterns  
**Yet:** unreliable (sensitivity <30% and specificity=60%)

•Can be positive (ELISA/Dot-blot) in some cases of SLE patients with negative ANA by conventional IIF.

**Confirmation techniques:**

- **ELISA**
- **Line/dot blot immunoassay:** comparable performance (sensitivity between 15%-25% for a specificity of 99%)
- **ALBIA**

